Compare Adaptive Biotechnologies Corp (ADPT) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Wheaton Precious Metals Corp — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Wheaton Precious Metals Corp trades at $107 (market cap $50.76B). The key difference: Wheaton Precious Metals Corp is far larger — about 15.2× Adaptive Biotechnologies Corp's market cap, and Wheaton Precious Metals Corp pays a 0.7% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WPM | |
|---|---|---|
Market Cap | $3.33B | $50.76B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $165.72 |
52-Week Low | $10.24 | $86.72 |
Enterprise Value | $3.19B | $48.61B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Wheaton Precious Metals (WPM) trades at $111.89, down 3.32% recently amid broader precious metals volatility. The stock shows strong fundamentals with record 2025 revenue of $2.31B and net income of $1.47B, supported by three consecutive quarterly EPS beats. Technical indicators signal bearish momentum with key support at $109, while analyst consensus remains strongly bullish with an $169 price target representing 51% upside potential from current levels.
WPM presents a compelling growth story with exceptional profitability margins (65.55% net income margin) and projected 2026 revenue growth to $2.7B. Primary risks include precious metal price volatility and geopolitical tensions affecting mining operations. The 80% buy rating from analysts suggests significant upside potential despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
